hypereosinophilic syndrome
Information
- Disease name
- hypereosinophilic syndrome
- Disease ID
- DOID:999
- Description
- "A leukocyte disease that is characterized by high numbers of eosinophils which over time enter various tissues, eventually damaging organs." [url:https\://en.wikipedia.org/wiki/Hypereosinophilic_syndrome, url:https\://www.mayoclinic.org/diseases-conditions/hypereosinophilic-syndrome/symptoms-causes/syc-20352854]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00255346 | Completed | Phase 2 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | November 15, 2005 | March 3, 2017 |
| NCT00787384 | Completed | Phase 2 | Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes | October 2004 | December 2007 |
| NCT01524536 | Completed | Phase 4 | Steroid Treatment for Hypereosinophilic Syndrome | February 16, 2012 | December 10, 2020 |
| NCT00086658 | Completed | Phase 3 | Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) | March 23, 2004 | May 1, 2006 |
| NCT00038675 | Completed | N/A | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | June 2001 | November 2013 |
| NCT00017862 | Completed | Phase 2 | Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome | June 2001 | June 2003 |
| NCT00109707 | Completed | Phase 1/Phase 2 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | April 2005 | September 2012 |
| NCT03306043 | Completed | Phase 3 | A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 | November 13, 2017 | December 30, 2019 |
| NCT00171912 | Completed | Phase 2 | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | September 2004 | January 2012 |
| NCT02836496 | Completed | Phase 3 | Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) | March 7, 2017 | August 8, 2019 |
| NCT01713504 | Completed | N/A | Identification of New Markers in the Hypereosinophilic Syndrome | June 29, 2010 | July 2015 |
| NCT00244686 | No longer available | This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic | |||
| NCT05334368 | Recruiting | Phase 3 | Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | September 6, 2022 | March 26, 2026 |
| NCT00044304 | Recruiting | Phase 2 | Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome | September 26, 2002 | January 1, 2026 |
| NCT00091871 | Recruiting | A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression | June 8, 2005 | ||
| NCT03801434 | Recruiting | Phase 2 | Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders | November 15, 2019 | November 30, 2025 |
| NCT04018118 | Recruiting | Natural History of Hypereosinophilia and Hypereosinophilic Syndromes | May 6, 2019 | May 2031 | |
| NCT04191304 | Recruiting | Phase 3 | A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) | July 20, 2020 | November 20, 2026 |
| NCT04965636 | Recruiting | Phase 3 | Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) | August 24, 2022 | September 16, 2024 |
| NCT00171860 | Terminated | Phase 2 | A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome | September 2002 | |
| NCT00097370 | Terminated | Phase 3 | Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome | September 30, 2004 | September 29, 2010 |
| NCT00230334 | Terminated | Phase 2 | Phase II Gleevec Idiopathic Hypereosinophilic Syndrome | June 12, 2003 | May 2007 |
| NCT00276926 | Unknown status | Phase 2 | Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias | March 2003 | |
| NCT02101138 | Unknown status | Phase 2 | Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome | March 14, 2014 | October 23, 2019 |
| NCT02581514 | Unknown status | N/A | Eosinophilia Diagnosis | October 2015 | November 2019 |
- Disase is a (Disease Ontology)
- DOID:9500
- Cross Reference ID (Disease Ontology)
- GARD:2804
- Cross Reference ID (Disease Ontology)
- ICD10CM:D72.1
- Cross Reference ID (Disease Ontology)
- ICD9CM:288.3
- Cross Reference ID (Disease Ontology)
- MESH:D004802
- Cross Reference ID (Disease Ontology)
- ORDO:168956
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:418928000
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0014457
- Exact Synonym (Disease Ontology)
- eosinophilia
- Exact Synonym (Disease Ontology)
- Eosinophilic leukocytosis
- OrphaNumber from OrphaNet (Orphanet)
- 168956
- MeSH unique ID (MeSH (Medical Subject Headings))
- D017681